ZA200609111B - Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands - Google Patents

Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Info

Publication number: ZA200609111B
Authority: ZA; South Africa
Prior art keywords: histamine; receptor ligands; derivatives useful; tetrahydronaphthyridine derivatives; tetrahydronaphthyridine
Prior art date: 2004-05-12

Application number

ZA200609111A

Other languages

English (en)

Inventor

Lunn Graham

Strang Ross Sinclair

Mathias John Paul

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-12

Filing date

2006-11-01

Publication date

2008-08-27

2006-11-01 Application filed by Pfizer filed Critical Pfizer

2008-08-27 Publication of ZA200609111B publication Critical patent/ZA200609111B/xx

Links

ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical class C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 title 1
102000004384 Histamine H3 receptors Human genes 0.000 title 1
108090000981 Histamine H3 receptors Proteins 0.000 title 1
239000003446 ligand Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Hydrogenated Pyridines (AREA)

ZA200609111A 2004-05-12 2006-11-01 Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands ZA200609111B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04291222A EP1595881A1 (de)	2004-05-12	2004-05-12	Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden

Publications (1)

Publication Number	Publication Date
ZA200609111B true ZA200609111B (en)	2008-08-27

Family

ID=34931096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200609111A ZA200609111B (en)	2004-05-12	2006-11-01	Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Country Status (32)

Country	Link
US (2)	US7557121B2 (de)
EP (2)	EP1595881A1 (de)
JP (1)	JP4084410B2 (de)
KR (1)	KR100908155B1 (de)
CN (2)	CN101798305A (de)
AP (1)	AP2006003786A0 (de)
AR (1)	AR049092A1 (de)
AT (1)	ATE491707T1 (de)
AU (1)	AU2005243403B2 (de)
BR (1)	BRPI0510762A (de)
CA (1)	CA2564201C (de)
CR (1)	CR8747A (de)
DE (1)	DE602005025345D1 (de)
DK (1)	DK1756104T3 (de)
EA (1)	EA010487B1 (de)
EC (1)	ECSP066984A (de)
ES (1)	ES2355572T3 (de)
GE (1)	GEP20084552B (de)
GT (1)	GT200500112A (de)
IL (1)	IL178882A (de)
MA (1)	MA28579B1 (de)
MX (1)	MXPA06013113A (de)
NL (1)	NL1029016C2 (de)
NO (1)	NO20064577L (de)
PA (1)	PA8632801A1 (de)
PE (1)	PE20060312A1 (de)
SV (1)	SV2005002112A (de)
TN (1)	TNSN06369A1 (de)
TW (1)	TW200607506A (de)
UY (1)	UY28895A1 (de)
WO (1)	WO2005111036A1 (de)
ZA (1)	ZA200609111B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6468306B1 (en)	1998-05-29	2002-10-22	Advanced Medical Optics, Inc	IOL for inhibiting cell growth and reducing glare
US7621949B2 (en)	2003-12-09	2009-11-24	Advanced Medical Optics, Inc.	Foldable intraocular lens and method of making
DE602006002894D1 (de)	2005-06-17	2008-11-06	Janssen Pharmaceutica Nv	Naphthyridinverbindungen
US8158673B2 (en)	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
EP1945639A1 (de) *	2005-11-04	2008-07-23	Pfizer Limited	Tetrahydronaphthyridinderivat
WO2007099423A1 (en) *	2006-03-02	2007-09-07	Pfizer Products Inc.	1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009531314A (ja)	2006-03-10	2009-09-03	ニューロジェン・コーポレーション	ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
CA2655604C (en)	2006-06-23	2016-08-09	Abbott Laboratories	Cyclopropyl amine derivatives
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
EP2216023A4 (de) *	2007-11-15	2013-03-13	Takeda Pharmaceutical	Kondensiertes pyridinderivat und seine verwendung
WO2009082698A1 (en) *	2007-12-21	2009-07-02	Abbott Laboratories	Compositions for treatment of cognitive disorders
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
EA201001329A1 (ru) *	2008-02-22	2011-04-29	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
JP2011518127A (ja) *	2008-03-31	2011-06-23	エヴォテック・アクチエンゲゼルシャフト	ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
WO2010026113A1 (en) *	2008-09-03	2010-03-11	Evotec Neurosciences Gmbh	Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010052222A1 (en) *	2008-11-07	2010-05-14	Evotec Neurosciences Gmbh	(dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
EP2421863A1 (de) *	2009-04-21	2012-02-29	NeuroSearch AS	Substituierte naphthyridinderivate und deren medizinische verwendung
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8711772B2 (en) *	2009-05-22	2014-04-29	Qualcomm Incorporated	Paging of a user equipment (UE) within a wireless communications system
US20120101106A1 (en) *	2009-07-09	2012-04-26	Mercer Swati P	Tetrahydronapthyridine Orexin Receptor Antagonists
WO2012037258A1 (en)	2010-09-16	2012-03-22	Abbott Laboratories	Processes for preparing 1,2-substituted cyclopropyl derivatives
CN102093356B (zh) *	2011-03-16	2012-12-19	无锡美克赛医药科技有限公司	一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
WO2012131539A1 (en)	2011-03-31	2012-10-04	Pfizer Inc.	Novel bicyclic pyridinones
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
JP6043355B2 (ja)	2011-08-31	2016-12-14	ファイザー・インク	ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
MD20140130A2 (ro)	2012-06-29	2015-04-30	Pfizer Inc.	4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
CA2882389A1 (en)	2012-09-20	2014-03-27	Pfizer Inc.	Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
WO2014091352A1 (en)	2012-12-11	2014-06-19	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en)	2012-12-19	2017-10-24	Pfizer Inc.	Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
AP2015008663A0 (en)	2013-02-19	2015-08-31	Pfizer	Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
AP2015008843A0 (en)	2013-05-02	2015-11-30	Pfizer	Imidazo-triazine derivatives as pde10 inhibitors
CA2925743C (en)	2013-10-04	2018-03-06	Pfizer Inc.	Novel bicyclic pyridinones as gamma-secretase modulators
WO2015092592A1 (en)	2013-12-17	2015-06-25	Pfizer Inc.	Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
PE20161364A1 (es)	2014-04-01	2016-12-25	Pfizer	CROMENO Y 1,1a,2,7b-TETRAHIDROCICLOPROPA [C] CROMENO PIRIDOPIRAZINADIONAS NOVEDOSAS
CR20160455A (es)	2014-04-10	2016-12-16	Pfizer	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILA
EP3172210B1 (de)	2014-07-24	2020-01-15	Pfizer Inc	Pyrazolopyrimidin verbindungen
SG11201700243YA (en)	2014-08-06	2017-02-27	Pfizer	Imidazopyridazine compounds
TN2017000342A1 (en)	2015-02-03	2019-01-16	Pfizer	Novel cyclopropabenzofuranyl pyridopyrazinediones
KR20180011272A (ko) *	2015-05-28	2018-01-31	세라밴스 바이오파마 알앤디 아이피, 엘엘씨	Jak 키나제 저해제로서 나프티리딘 화합물
ES2832893T3 (es)	2015-06-17	2021-06-11	Pfizer	Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CN108137586B (zh)	2015-09-14	2021-04-13	辉瑞大药厂	作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
EP3353174A1 (de)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-dimethyl-1,1-dioxid-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)]-1,3-thiazol-4-yl-amide als bace-hemmer
WO2017051276A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja)	2015-09-24	2018-11-01	ファイザー・インク	テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
PL3419979T3 (pl)	2016-02-23	2020-06-29	Pfizer Inc.	Związki 6,7-dihydro-5h-pirazolo[5,1-b][1,3]oksazyno-2- karboksyamidowe
HUE054857T2 (hu)	2016-07-01	2021-10-28	Pfizer	5,7-dihidro-pirrolo-piridinszármazékok neurológiai és neurodegeneratív betegségek kezelésére
WO2018163066A1 (en)	2017-03-10	2018-09-13	Pfizer Inc.	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018163030A1 (en)	2017-03-10	2018-09-13	Pfizer Inc.	Cyclic substituted imidazo[4,5-c]quinoline derivatives
EP3634978A1 (de)	2017-06-07	2020-04-15	Adrx, Inc.	Tau-aggregationshemmer
CN110944998B (zh)	2017-06-22	2022-08-16	辉瑞大药厂	二氢-吡咯并-吡啶衍生物
EP3668886A2 (de)	2017-08-18	2020-06-24	Adrx, Inc.	Peptidinhibitoren der tau-aggregation
ES2942837T3 (es)	2018-03-23	2023-06-07	Pfizer	Derivados de azaespiro piperazina
WO2022182658A1 (en)	2021-02-23	2022-09-01	Hoth Therapeutics, Inc.	Use of aprepitant for treating alzheimer's disease
KR20240012534A (ko) *	2021-05-21	2024-01-29	청두 바이위 파머수티컬 씨오., 엘티디	피페라진 유도체 및 이의 의학적 용도
WO2025145091A1 (en)	2023-12-29	2025-07-03	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU709611B2 (en)	1996-02-09	1999-09-02	James Black Foundation Limited	Histamine h3 receptor ligands
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9803536D0 (en) *	1998-02-19	1998-04-15	Black James Foundation	Histamine H,receptor ligands
EP0982300A3 (de)	1998-07-29	2000-03-08	Societe Civile Bioprojet	Alkylamine ohne Imidazolring als Histamin-H3-antagonisten und deren therapeutische Anwendung
TWI298068B (en) *	2000-06-21	2008-06-21	Dainippon Sumitomo Pharma Co	Pharmaceutical composition for schizophrenia
JP4516717B2 (ja)	2000-07-13	2010-08-04	アボット・ラボラトリーズ	ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用
KR100852362B1 (ko)	2000-08-08	2008-08-14	오르토-맥네일 파마슈티칼, 인코퍼레이티드	비-이미다졸 아릴옥시피페리딘
ATE319696T1 (de) *	2000-08-08	2006-03-15	Ortho Mcneil Pharm Inc	Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
WO2002076925A2 (en)	2001-03-23	2002-10-03	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0206033D0 (en) *	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
CA2532236C (en) *	2003-07-29	2011-08-23	Novo Nordisk A/S	Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
EP1945639A1 (de) *	2005-11-04	2008-07-23	Pfizer Limited	Tetrahydronaphthyridinderivat

2004
- 2004-05-12 EP EP04291222A patent/EP1595881A1/de not_active Withdrawn
2005
- 2005-05-06 KR KR1020067023573A patent/KR100908155B1/ko not_active Expired - Fee Related
- 2005-05-06 WO PCT/IB2005/001267 patent/WO2005111036A1/en not_active Ceased
- 2005-05-06 ES ES05736116T patent/ES2355572T3/es not_active Expired - Lifetime
- 2005-05-06 GE GEAP20059701A patent/GEP20084552B/en unknown
- 2005-05-06 AU AU2005243403A patent/AU2005243403B2/en not_active Ceased
- 2005-05-06 EP EP05736116A patent/EP1756104B1/de not_active Expired - Lifetime
- 2005-05-06 EA EA200601897A patent/EA010487B1/ru not_active IP Right Cessation
- 2005-05-06 DE DE602005025345T patent/DE602005025345D1/de not_active Expired - Lifetime
- 2005-05-06 MX MXPA06013113A patent/MXPA06013113A/es active IP Right Grant
- 2005-05-06 JP JP2007512575A patent/JP4084410B2/ja not_active Expired - Fee Related
- 2005-05-06 CN CN201010150783A patent/CN101798305A/zh active Pending
- 2005-05-06 AT AT05736116T patent/ATE491707T1/de not_active IP Right Cessation
- 2005-05-06 CN CN2005800150008A patent/CN1950371B/zh not_active Expired - Fee Related
- 2005-05-06 CA CA2564201A patent/CA2564201C/en not_active Expired - Fee Related
- 2005-05-06 DK DK05736116.4T patent/DK1756104T3/da active
- 2005-05-06 BR BRPI0510762-8A patent/BRPI0510762A/pt not_active IP Right Cessation
- 2005-05-06 AP AP2006003786A patent/AP2006003786A0/xx unknown
- 2005-05-11 NL NL1029016A patent/NL1029016C2/nl not_active IP Right Cessation
- 2005-05-11 AR ARP050101916A patent/AR049092A1/es unknown
- 2005-05-11 TW TW094115276A patent/TW200607506A/zh unknown
- 2005-05-12 UY UY28895A patent/UY28895A1/es not_active Application Discontinuation
- 2005-05-12 PE PE2005000533A patent/PE20060312A1/es not_active Application Discontinuation
- 2005-05-12 US US11/128,804 patent/US7557121B2/en not_active Expired - Fee Related
- 2005-05-12 SV SV2005002112A patent/SV2005002112A/es not_active Application Discontinuation
- 2005-05-12 PA PA20058632801A patent/PA8632801A1/es unknown
- 2005-05-12 GT GT200500112A patent/GT200500112A/es unknown
2006
- 2006-10-09 NO NO20064577A patent/NO20064577L/no not_active Application Discontinuation
- 2006-10-26 IL IL178882A patent/IL178882A/en not_active IP Right Cessation
- 2006-11-01 ZA ZA200609111A patent/ZA200609111B/xx unknown
- 2006-11-09 EC EC2006006984A patent/ECSP066984A/es unknown
- 2006-11-10 TN TNP2006000369A patent/TNSN06369A1/fr unknown
- 2006-11-10 CR CR8747A patent/CR8747A/es unknown
- 2006-11-10 MA MA29447A patent/MA28579B1/fr unknown
2009
- 2009-06-25 US US12/491,370 patent/US20090258861A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE602005025345D1 (de)	2011-01-27
EP1756104B1 (de)	2010-12-15
DK1756104T3 (da)	2011-02-21
US20090258861A1 (en)	2009-10-15
CR8747A (es)	2006-12-05
EP1595881A1 (de)	2005-11-16
ATE491707T1 (de)	2011-01-15
NO20064577L (no)	2006-11-06
KR100908155B1 (ko)	2009-07-16
WO2005111036A1 (en)	2005-11-24
TW200607506A (en)	2006-03-01
IL178882A0 (en)	2007-03-08
GEP20084552B (en)	2008-11-25
UY28895A1 (es)	2005-12-30
JP2007536374A (ja)	2007-12-13
ECSP066984A (es)	2006-12-29
CA2564201A1 (en)	2005-11-24
CN1950371A (zh)	2007-04-18
EP1756104A1 (de)	2007-02-28
US20050256135A1 (en)	2005-11-17
CA2564201C (en)	2011-01-18
KR20070014174A (ko)	2007-01-31
US7557121B2 (en)	2009-07-07
JP4084410B2 (ja)	2008-04-30
NL1029016C2 (nl)	2006-05-30
NL1029016A1 (nl)	2005-11-15
BRPI0510762A (pt)	2007-11-20
MA28579B1 (fr)	2007-05-02
CN101798305A (zh)	2010-08-11
PA8632801A1 (es)	2006-06-02
PE20060312A1 (es)	2006-05-03
EA010487B1 (ru)	2008-10-30
AU2005243403A1 (en)	2005-11-24
MXPA06013113A (es)	2007-02-28
AP2006003786A0 (en)	2006-10-31
CN1950371B (zh)	2011-01-12
SV2005002112A (es)	2005-12-13
TNSN06369A1 (fr)	2008-02-22
AR049092A1 (es)	2006-06-28
EA200601897A1 (ru)	2007-02-27
ES2355572T3 (es)	2011-03-29
AU2005243403B2 (en)	2010-10-07
IL178882A (en)	2011-03-31
GT200500112A (es)	2005-12-12

Publication	Publication Date	Title
IL178882A0 (en)	2007-03-08	Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands
ZA200700683B (en)	2008-08-27	Piperidine derivatives as histamine H3 receptor ligands
ZA200703912B (en)	2008-09-25	3-arylamino pyridine derivatives
IL180430A0 (en)	2007-06-03	Pyridine derivatives
TWI369356B (en)	2012-08-01	Tetrahydropyridoindole derivatives
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
ZA200610102B (en)	2008-08-27	Pyrrazolo-pyrimidine derivatives
PL1802307T3 (pl)	2008-07-31	Pochodne pirolidyny jako ligandy receptorów histaminowych
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
ZA200703172B (en)	2008-08-27	Imidazo-benzodiazepine derivatives
GB0512335D0 (en)	2005-07-27	Merocyanine derivatives
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
EP1713917A4 (de)	2009-06-17	Pneumolysinderivate
IL179444A0 (en)	2007-05-15	4-phenyl-pyrimidine-2-carbonitrile derivatives
TWI346109B (en)	2011-08-01	4-amino-5-cyanopyrimidine derivatives
PL1636223T3 (pl)	2008-07-31	Pochodne benzotiazolu jako ligandy receptora adenozynowego
IL188924A0 (en)	2008-08-07	Imidazopyridine derivatives as cannabinoid receptor ligands
ZA200705106B (en)	2008-12-31	Nicotinic acetycholine receptor ligands
IL182001A0 (en)	2007-07-04	2-acylaminothiazole derivatives
ZA200800354B (en)	2008-12-31	Imidazopyridine derivatives as cannabinoid receptor ligands
HK1102817A (en)	2007-12-07	Piperidine derivatives as histamine h3 receptor ligands
GB0411078D0 (en)	2004-06-23	Bicyclic derivatives
GB0416524D0 (en)	2004-08-25	Pyridine derivatives
ZA200600676B (en)	2007-03-28	Pyridazinyl-piperazines and their use as histamine H3 receptor ligands
HK1117508A (en)	2009-01-16	Imidazopyridine derivatives as cannabinoid receptor ligands